Tildrakizumab is a monoclonal antibody that specifically targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. It is primarily used in the treatment of moderate to severe plaque psoriasis. As a humanized IgG1κ antibody, Tildrakizumab works by inhibiting the interaction between IL-23 and its receptor, thereby reducing the inflammatory response associated with autoimmune conditions. The molecular structure of Tildrakizumab allows for high specificity and affinity for IL-23, contributing to its therapeutic efficacy. It is administered via subcutaneous injection and has a favorable pharmacokinetic profile, allowing for dosing at intervals that can range from every few weeks to several months, depending on the treatment regimen. Common side effects may include injection site reactions, upper respiratory infections, and headaches, but it is generally well-tolerated. As with other biologics, monitoring for potential infections and other immune-related effects is essential during treatment. Overall, Tildrakizumab represents a targeted approach in the management of psoriasis, reflecting advancements in biologic therapies.

Tildrakizumab

1326244-10-3: Immunoglobulin G1, anti-(human interleukin 23) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer, Tildrakizumab-asmn, Ilumya, Tildrakizumab, Ilumetri

Tildrakizumab (SCH 900222) is a humanized antibody against IL-23, with a 136 pM Kd, used for psoriasis research.

Anti-Interleukin 23 monoclonal antibody, treatment of immunologically mediated inflammatory disorders

CAS 1326244-10-3: Tildrakizumab

Tildrakizumab

Ref: TM-T76784

Tildrakizumab

Ref: 3D-CLA1317